Bupropion/dextromethorphan

Bupropion/dextromethorphan
Combination of
Bupropion Norepinephrine reuptake inhibitor and nicotinic acetylcholine receptor antagonist
Dextromethorphan Sigma-1 receptor agonist, NMDA receptor antagonist, serotonin-norepinephrine reuptake inhibitor
Clinical data
Routes of
administration		 Oral
Legal status
Legal status

Bupropion/dextromethorphan (developmental code name AXS-05) is a combination formulation of bupropion (Wellbutrin), a norepinephrine-dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor (nAChR) antagonist, and dextromethorphan (DXM), a sigma-1 receptor agonist, NMDA receptor antagonist, and serotonin-norepinephrine reuptake inhibitor (SNRI), which is under development by Axsome Therapeutics for the treatment of treatment-resistant major depressive disorder (MDD) and agitation in Alzheimer's disease.[1] Via inhibition of CYP2D6, similarly to quinidine, bupropion slows the metabolism of DXM and thereby increases its levels. As of 2017, the combination is in phase III clinical trials for the aforementioned indications.[1]

See also

References



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.